financetom
Business
financetom
/
Business
/
Stellantis recalls 54,000 hybrid SUVs worldwide over brake pedal defect
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stellantis recalls 54,000 hybrid SUVs worldwide over brake pedal defect
Oct 17, 2024 1:46 PM

*

Alfa Romeo Tonale, Dodge Hornet plug-in hybrids affected

*

Stellantis ( STLA ) cites 15 brake pedal failures, with one crash

WASHINGTON, Oct 16 (Reuters) - Carmaker Stellantis

said on Wednesday it is recalling 54,000 hybrid

crossover SUVs worldwide because the brake pedal in the vehicles

could disengage and stop working.

The recall, the company said, includes some 2024 through

2025 model-year Alfa Romeo Tonale plug-in hybrid SUVs and some

2024 model-year Dodge Hornet plug-in SUVs that are based on the

same platform.

The announcement was made in a filing with the U.S. National

Highway Traffic Safety Administration and a separate statement

by Stellantis ( STLA ). The recall includes 21,069 vehicles in the United

States, about 2,280 in Canada, 134 in Mexico and about 30,517

outside North America, Stellantis ( STLA ) said.

The company said that some SUVs may have a brake pedal that

could inadvertently disengage while being applied. Stellantis ( STLA )

said it was aware of 15 instances globally of the brake pedal

assemblies collapsing during normal driving, including one

crash, with no injuries reported.

Dealers will reinforce the brake pedal by adding a bolt and

nut, Stellantis ( STLA ) said.

The company said that owners of affected models could also

use the electronic parking brake to slow the vehicle in a

controlled manner if they encounter a loss of braking power.

Stellantis ( STLA ) said the automatic emergency braking system, unless

deactivated, will intervene without further action by the driver

when it detects that a collision is imminent.

Stellantis ( STLA ) said it has sold 15,566 Hornets and 2,737 Tonales

in the United States this year through Sept. 30.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved